<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091116</url>
  </required_header>
  <id_info>
    <org_study_id>BKOS-02</org_study_id>
    <secondary_id>2009-014918-99</secondary_id>
    <nct_id>NCT01091116</nct_id>
  </id_info>
  <brief_title>A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS</brief_title>
  <acronym>ALBATROSS</acronym>
  <official_title>Intra-articular Treatment With MEN16132 in Patients With Symptomatic Primary Osteoarthritis of the Knee: A Randomized, Multi-centre, Double Blind, Placebo Controlled, Five Parallel Group, Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intra-articular (knee joint) administration
      of MEN16132 is effective reducing the pain from knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MEN16132 is a non-peptide bradykinin B2-receptor antagonist showing analgesic and
      anti-inflammatory activity in nonclinical osteoarthritis models. This study is being
      conducted as a dose finding study to determine the safety and efficacy of MEN16132, given as
      three doses/four treatment regimens in comparison to placebo, as well the time to onset and
      duration of effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC VA 3.1 A Score (Total Pain)</measure>
    <time_frame>over the 3 weeks after the first administration</time_frame>
    <description>Western Ontario and McMaster Universities osteoarthritis index (WOMAC). The WOMAC VA 3.1 A score (total pain , range 0-500 mm) is the sum of VAS scores (0-100 mm) attributed by the patient to each of the 5 questions referring to osteoarthritic pain experienced during the preceding 48 hours.
The higher is the WOMAC VA 3.1 A score, the higher is the intensity of pain symptoms (0 = no pain ; 500 = extreme pain).
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.
The change from baseline was assessed along 3 weeks after first drug administrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC VA 3.1.B Score (Knee Stiffness)</measure>
    <time_frame>up to 3 months after first dose</time_frame>
    <description>WOMAC VA 3.1.B score(range 0-200) is the sum of VAS scores (0-100 mm)attributed by the patient to each of the 2 questions referring to joint stiffness experienced during the preceding 48 hours. The higher is the WOMAC VA 3.1 B score, the higher is joint stiffness (0 = no stiffness ; 200 = extreme stiffness).
A decrease of the WOMAC VA 3.1 B score following treatment administration indicates a reduction of joint stiffness.
The change at Week 13 from baseline is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC VA 3.1. C Score (Function)</measure>
    <time_frame>up to 3 months after first dose</time_frame>
    <description>Knee function evaluated by WOMAC VA 3.1 C score (range 0-1700) is the sum of VAS scores (range 0-100 mm) attributed by the patient to each of 17 questions referring to difficulty in performing daily activities experienced during the preceding 48 hours.
The higher is the WOMAC VA 3.1 C score, the higher is functional impairment in daily activities (0 = no difficulty ; 1700 = extreme difficulty).
A decrease of the WOMAC VA 3.1 C score following treatment administration indicates an improvement in performing daily activities.
WOMAC VA 3.1.C scores at baseline and at Week 13 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Treatment Responders According to OMERACT-OARSI Responder Criteria</measure>
    <time_frame>up to 3 months after first dose</time_frame>
    <description>Osteoarthritis Research Society International (OARSI).
Response defined as:
a decrease in WOMAC pain or physical-function score by 50% or more and by 20 or more points on the visual analogue scale
OR if two of the following three findings are recorded:
a decrease in the WOMAC pain score by 20% or more and by 10 or more points on the visual analogue scale; a decrease in the WOMAC physical-function score by 20% or more and by 10 or more points on the scale; an improvement in the score on the patient's global assessment by 20% or more and by 10 or more points on the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>up to 3 months after first dose</time_frame>
    <description>Patient global assessment evaluated using a VAS scale score attributed by the patient (range 0-100 mm).
Efficacy assessed as change at each time-point post-dosing (week 1, 2 ,3, 13) versus baseline (week 0).
A decrease of patient global assessment score indicates an improvement of osteoarthritis symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC VA 3.1A - Total Pain Score by Body Mass Index [BMI &lt;= 25]</measure>
    <time_frame>over the 3 weeks after the first administration</time_frame>
    <description>Analysis in normal-weight population (BMI &lt;= 25) of the WOMAC VA 3.1A score (range 0-500 mm) is reported.
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC VA 3.1A - Total Pain Score by Body Mass Index -[BMI &gt; 25]</measure>
    <time_frame>over the 3 weeks after the first administration</time_frame>
    <description>Analysis in over-weight population (BMI &gt; 25) of the WOMAC VA 3.1A score (range 0-500 mm) is reported.
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Reports</measure>
    <time_frame>up to 4 months after screening</time_frame>
    <description>Incidence of spontaneously reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Abnormal Laboratory Tests</measure>
    <time_frame>up to 4 months from screening</time_frame>
    <description>Percentage of patients with Abnormal Laboratory Tests judged Clinically Significant by Investigators.
The following hematochemical and urinary parameters were analysed:
Red Blood Cells Count, Haematocrit, Haemoglobin, Platelets, MCV, MCH, MCHC, White Blood Cells, Sodium, Chloride, Potassium, Total calcium, AST (SGOT), ALT (SGPT), GGT, Alkaline phosphatase, Total Bilirubin, Direct Bilirubin, Creatinine, BUN, CPK, LDH, Glucose, Total proteins, Albumin.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">423</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Double dose MEN16132 0.125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double dose MEN16132 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double dose MEN16132 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose MEN16132 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-articular administration of two doses of Placebo at 2-week interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEN16132 - 0.125 mg</intervention_name>
    <description>Intra-articular administration of two low doses of MEN16132 at 2-week interval.</description>
    <arm_group_label>Double dose MEN16132 0.125 mg</arm_group_label>
    <other_name>fasitibant 0.125 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEN16132 - 0.25 mg</intervention_name>
    <description>Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval</description>
    <arm_group_label>Double dose MEN16132 0.25 mg</arm_group_label>
    <other_name>fasitibant 0.25 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEN16132 - 0.5 mg</intervention_name>
    <description>Intra-articular injection of two high doses of MEN16132 at 2-week interval</description>
    <arm_group_label>Double dose MEN16132 0.5 mg</arm_group_label>
    <other_name>fasitibant 0.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEN16132 - 0.5 mg</intervention_name>
    <description>Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval</description>
    <arm_group_label>Single dose MEN16132 0.5 mg</arm_group_label>
    <other_name>fasitibant 0.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intra-articular injection of 2 doses of Placebo control at 2-week interval</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male or female patients ≥40 years old.

          -  Symptomatic primary knee osteoarthritis (ACR criteria) since ≥6 months prior to
             screening, Kellgren Lawrence Grade 2 or 3, and representing an indication for
             intra-articular drug injection.

          -  &gt;50 mm VAS pain score assigned to the index knee at WOMAC VA 3.1-A1 (pain while
             walking on a flat surface).

          -  &gt;125 mm VAS pain score assigned to the index knee at WOMAC VA 3.1 A subscore (total
             pain).

          -  Pain in the index knee on at least 50% of the days in the month preceding the
             screening.

        Main Exclusion Criteria:

          -  Patients with Kellgren &amp; Lawrence Grade I or IV (doubtful or severe) osteoarthritis of
             the knee.

          -  Knee condition representing an indication for surgery

          -  Patients with Inflammatory or crystal arthropathies, acute fractures, severe loss of
             bone density, bone necrosis.

          -  Patients with isolated patella-femoral syndrome or chondromalacia.

          -  Patients with OA predominant in the lateral compartment or any significant valgus
             deformity.

          -  Patients with any other disease or condition interfering with the free use and
             evaluation of the index knee for the 3 month duration of the trial (e.g. cancer,
             congenital defects, spine osteoarthritis).

          -  Major injury or surgery to the index knee within the previous 12 months prior to
             screening.

          -  Severe hip osteoarthritis ipsilateral to index knee.

          -  Any pain &gt;30 mm VAS that could interfere with the assessment of index knee pain (e.g.
             pain in any other part of the lower extremities, pain radiating to the knee).

          -  Any pharmacological or non-pharmacological treatment started or changed during 4 weeks
             prior to randomisation or likely to be changed during the duration of the study

          -  Use of systemic or topical corticosteroids &gt;10 mg prednisolone equivalent per day
             during 30 days prior to randomisation.

          -  Use of any pain or OA medication (e.g. NSAIDs, COX-2 inhibitors, analgesics) during 1
             or 2 weeks prior to randomisation.

          -  Any intra-articular or local periarticular punction, injection or surgery to the index
             knee during the 6 months prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karel Pavelka, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Rheumatology, Charles University Prague</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Régional - Hôpital Porte Madeleine</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu - GHU Ouest</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Purpan University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologie/Immunologie - Rheumazentrum, Krankenhaus Doberan</name>
      <address>
        <city>Bad Doberan</city>
        <zip>18209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Rheumatologie und Klinische Immunologie, Charité - Campus Charité Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Praxis Dr. Wagenitz</name>
      <address>
        <city>Berlin</city>
        <zip>12247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International, Prüfzentrum Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International, Prüfzentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik 3, Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm Prüfzentrum Frankfurt / aM</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm Prüfzentrum Görlitz</name>
      <address>
        <city>Görlitz</city>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädie Zentrum Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International, Prüfzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm Prüfzentrum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio di Reumatologia, Ospedale Privato Accreditato Nigrisoli</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Biomedicina - SOD Reumatologia - Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna Azienda Ospedaliero Universitaria Pisana-Stabilimento di Santa Chiara Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Reumatologia, &quot;Policlinico Le Scotte&quot; Università degli Studi di Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Reumatologia, Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Reumatologia, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Reumatologia, Corporacio Sanitaria Parc Tauli, Hospital de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Reumatologia, Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2010</study_first_posted>
  <results_first_submitted>November 8, 2012</results_first_submitted>
  <results_first_submitted_qc>January 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 18, 2013</results_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Injections, Intra-Articular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(4-amino-5-(4-(4-(2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido)tetrahydro-2H-4-pyranoylcarbonyl)piperazino)-5-oxopentyl)(trimethyl)ammonium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Outpatients were recruited from March 2010 to November 2010 in private practice and hospitals.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>two intra-articular fasitibant doses; 0.125 mg each</description>
        </group>
        <group group_id="P2">
          <title>Mid Dose</title>
          <description>two intra-articular fasitibant doses; 0.25 mg each</description>
        </group>
        <group group_id="P3">
          <title>High Dose</title>
          <description>two intra-articular fasitibant doses; 0.5 mg each</description>
        </group>
        <group group_id="P4">
          <title>Single High Dose</title>
          <description>one intra-articular fasitibant dose 0.5 mg +placebo</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>two intra-articular placebo doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>two doses</description>
        </group>
        <group group_id="B2">
          <title>Mid Dose</title>
          <description>two doses</description>
        </group>
        <group group_id="B3">
          <title>High Dose</title>
          <description>two doses</description>
        </group>
        <group group_id="B4">
          <title>Single High Dose</title>
          <description>one dose+placebo</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>two doses</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="84"/>
            <count group_id="B4" value="84"/>
            <count group_id="B5" value="84"/>
            <count group_id="B6" value="423"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="9.0"/>
                    <measurement group_id="B2" value="65.9" spread="9.5"/>
                    <measurement group_id="B3" value="65.1" spread="9.7"/>
                    <measurement group_id="B4" value="65.3" spread="8.7"/>
                    <measurement group_id="B5" value="65.1" spread="8.5"/>
                    <measurement group_id="B6" value="65.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of osteoarthritis symptoms</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="9.2"/>
                    <measurement group_id="B2" value="8.0" spread="6.3"/>
                    <measurement group_id="B3" value="7.9" spread="6.6"/>
                    <measurement group_id="B4" value="8.2" spread="8.4"/>
                    <measurement group_id="B5" value="6.5" spread="6.4"/>
                    <measurement group_id="B6" value="8.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Radiographic Osteoarthritis severity</title>
          <description>Based on Kellgren &amp; Lawrence radiologic scale criteria (Grade 1 to 4):
narrowing of joint space
osteophytic stuctures
sclerosis
deformity of bone contour</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 1 Kellgren-Lawrence scale(doubtful severity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Kellgren-Lawrence scale(minimal severity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Kellgren-Lawrence scale(moderate severity)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Kellgren-Lawrence scale(severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing information</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WOMAC VA 3.1 A score (Total pain)</title>
          <description>Western Ontario and McMaster Universities osteoarthritis index (WOMAC). The WOMAC VA 3.1 A score (total pain, range 0-500 mm) is the sum of VAS subscores (0-100 mm) attributed by the patient to each of the 5 questions referring to osteoarthritic pain experienced during the preceding 48 hours (pain domain).
The higher is the WOMAC VA 3.1 A score, the higher is the intensity of pain symptoms (0 = no pain ; 500 = extreme pain).
A decrease of the WOMAC VA 3.1 A score following tratment administration indicates a reduction of pain symptom.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288" spread="80"/>
                    <measurement group_id="B2" value="282" spread="68"/>
                    <measurement group_id="B3" value="293" spread="73"/>
                    <measurement group_id="B4" value="283" spread="72"/>
                    <measurement group_id="B5" value="284" spread="79"/>
                    <measurement group_id="B6" value="286" spread="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>WOMAC VA 3.1 A Score (Total Pain)</title>
        <description>Western Ontario and McMaster Universities osteoarthritis index (WOMAC). The WOMAC VA 3.1 A score (total pain , range 0-500 mm) is the sum of VAS scores (0-100 mm) attributed by the patient to each of the 5 questions referring to osteoarthritic pain experienced during the preceding 48 hours.
The higher is the WOMAC VA 3.1 A score, the higher is the intensity of pain symptoms (0 = no pain ; 500 = extreme pain).
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.
The change from baseline was assessed along 3 weeks after first drug administrations.</description>
        <time_frame>over the 3 weeks after the first administration</time_frame>
        <population>analysis of the intention to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC VA 3.1 A Score (Total Pain)</title>
          <description>Western Ontario and McMaster Universities osteoarthritis index (WOMAC). The WOMAC VA 3.1 A score (total pain , range 0-500 mm) is the sum of VAS scores (0-100 mm) attributed by the patient to each of the 5 questions referring to osteoarthritic pain experienced during the preceding 48 hours.
The higher is the WOMAC VA 3.1 A score, the higher is the intensity of pain symptoms (0 = no pain ; 500 = extreme pain).
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.
The change from baseline was assessed along 3 weeks after first drug administrations.</description>
          <population>analysis of the intention to treat (ITT) population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60" spread="84"/>
                    <measurement group_id="O2" value="-58" spread="82"/>
                    <measurement group_id="O3" value="-52" spread="92"/>
                    <measurement group_id="O4" value="-67" spread="91"/>
                    <measurement group_id="O5" value="-63" spread="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69" spread="89"/>
                    <measurement group_id="O2" value="-65" spread="81"/>
                    <measurement group_id="O3" value="-71" spread="102"/>
                    <measurement group_id="O4" value="-73" spread="96"/>
                    <measurement group_id="O5" value="-75" spread="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-103" spread="107"/>
                    <measurement group_id="O2" value="-99" spread="86"/>
                    <measurement group_id="O3" value="-99" spread="104"/>
                    <measurement group_id="O4" value="-103" spread="99"/>
                    <measurement group_id="O5" value="-103" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Tests of Fixed Effects for the primary efficacy variable including baseline treatment and visit (from Visit 3 to Visit 5) as covariates</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5263</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC VA 3.1.B Score (Knee Stiffness)</title>
        <description>WOMAC VA 3.1.B score(range 0-200) is the sum of VAS scores (0-100 mm)attributed by the patient to each of the 2 questions referring to joint stiffness experienced during the preceding 48 hours. The higher is the WOMAC VA 3.1 B score, the higher is joint stiffness (0 = no stiffness ; 200 = extreme stiffness).
A decrease of the WOMAC VA 3.1 B score following treatment administration indicates a reduction of joint stiffness.
The change at Week 13 from baseline is reported.</description>
        <time_frame>up to 3 months after first dose</time_frame>
        <population>Intention to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC VA 3.1.B Score (Knee Stiffness)</title>
          <description>WOMAC VA 3.1.B score(range 0-200) is the sum of VAS scores (0-100 mm)attributed by the patient to each of the 2 questions referring to joint stiffness experienced during the preceding 48 hours. The higher is the WOMAC VA 3.1 B score, the higher is joint stiffness (0 = no stiffness ; 200 = extreme stiffness).
A decrease of the WOMAC VA 3.1 B score following treatment administration indicates a reduction of joint stiffness.
The change at Week 13 from baseline is reported.</description>
          <population>Intention to Treat (ITT) population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.7" spread="47.36"/>
                    <measurement group_id="O2" value="101.8" spread="39.70"/>
                    <measurement group_id="O3" value="109.4" spread="46.21"/>
                    <measurement group_id="O4" value="107.3" spread="43.30"/>
                    <measurement group_id="O5" value="108.7" spread="47.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="52.2"/>
                    <measurement group_id="O2" value="66.1" spread="47.4"/>
                    <measurement group_id="O3" value="64.5" spread="50.1"/>
                    <measurement group_id="O4" value="66.2" spread="49.3"/>
                    <measurement group_id="O5" value="63.4" spread="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC VA 3.1. C Score (Function)</title>
        <description>Knee function evaluated by WOMAC VA 3.1 C score (range 0-1700) is the sum of VAS scores (range 0-100 mm) attributed by the patient to each of 17 questions referring to difficulty in performing daily activities experienced during the preceding 48 hours.
The higher is the WOMAC VA 3.1 C score, the higher is functional impairment in daily activities (0 = no difficulty ; 1700 = extreme difficulty).
A decrease of the WOMAC VA 3.1 C score following treatment administration indicates an improvement in performing daily activities.
WOMAC VA 3.1.C scores at baseline and at Week 13 are reported.</description>
        <time_frame>up to 3 months after first dose</time_frame>
        <population>Intention to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC VA 3.1. C Score (Function)</title>
          <description>Knee function evaluated by WOMAC VA 3.1 C score (range 0-1700) is the sum of VAS scores (range 0-100 mm) attributed by the patient to each of 17 questions referring to difficulty in performing daily activities experienced during the preceding 48 hours.
The higher is the WOMAC VA 3.1 C score, the higher is functional impairment in daily activities (0 = no difficulty ; 1700 = extreme difficulty).
A decrease of the WOMAC VA 3.1 C score following treatment administration indicates an improvement in performing daily activities.
WOMAC VA 3.1.C scores at baseline and at Week 13 are reported.</description>
          <population>Intention to Treat (ITT) population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="928.7" spread="336.20"/>
                    <measurement group_id="O2" value="915.5" spread="285.20"/>
                    <measurement group_id="O3" value="906.7" spread="318.19"/>
                    <measurement group_id="O4" value="938.7" spread="300.63"/>
                    <measurement group_id="O5" value="936.5" spread="343.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537.5" spread="415.9"/>
                    <measurement group_id="O2" value="598.0" spread="396.9"/>
                    <measurement group_id="O3" value="574.6" spread="407.0"/>
                    <measurement group_id="O4" value="594.8" spread="444.3"/>
                    <measurement group_id="O5" value="557.6" spread="389.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Treatment Responders According to OMERACT-OARSI Responder Criteria</title>
        <description>Osteoarthritis Research Society International (OARSI).
Response defined as:
a decrease in WOMAC pain or physical-function score by 50% or more and by 20 or more points on the visual analogue scale
OR if two of the following three findings are recorded:
a decrease in the WOMAC pain score by 20% or more and by 10 or more points on the visual analogue scale; a decrease in the WOMAC physical-function score by 20% or more and by 10 or more points on the scale; an improvement in the score on the patient’s global assessment by 20% or more and by 10 or more points on the scale.</description>
        <time_frame>up to 3 months after first dose</time_frame>
        <population>intention to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Treatment Responders According to OMERACT-OARSI Responder Criteria</title>
          <description>Osteoarthritis Research Society International (OARSI).
Response defined as:
a decrease in WOMAC pain or physical-function score by 50% or more and by 20 or more points on the visual analogue scale
OR if two of the following three findings are recorded:
a decrease in the WOMAC pain score by 20% or more and by 10 or more points on the visual analogue scale; a decrease in the WOMAC physical-function score by 20% or more and by 10 or more points on the scale; an improvement in the score on the patient’s global assessment by 20% or more and by 10 or more points on the scale.</description>
          <population>intention to treat (ITT) population</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="35.6"/>
                    <measurement group_id="O3" value="36.6"/>
                    <measurement group_id="O4" value="41.5"/>
                    <measurement group_id="O5" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="37.0"/>
                    <measurement group_id="O4" value="47.6"/>
                    <measurement group_id="O5" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="67.5"/>
                    <measurement group_id="O3" value="54.4"/>
                    <measurement group_id="O4" value="57.3"/>
                    <measurement group_id="O5" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="59.8"/>
                    <measurement group_id="O4" value="64.6"/>
                    <measurement group_id="O5" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment</title>
        <description>Patient global assessment evaluated using a VAS scale score attributed by the patient (range 0-100 mm).
Efficacy assessed as change at each time-point post-dosing (week 1, 2 ,3, 13) versus baseline (week 0).
A decrease of patient global assessment score indicates an improvement of osteoarthritis symptoms.</description>
        <time_frame>up to 3 months after first dose</time_frame>
        <population>intention to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment</title>
          <description>Patient global assessment evaluated using a VAS scale score attributed by the patient (range 0-100 mm).
Efficacy assessed as change at each time-point post-dosing (week 1, 2 ,3, 13) versus baseline (week 0).
A decrease of patient global assessment score indicates an improvement of osteoarthritis symptoms.</description>
          <population>intention to treat (ITT) population</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="21.8"/>
                    <measurement group_id="O2" value="-3.3" spread="20.4"/>
                    <measurement group_id="O3" value="0.9" spread="18.5"/>
                    <measurement group_id="O4" value="-6.3" spread="23.6"/>
                    <measurement group_id="O5" value="-7.8" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="19.6"/>
                    <measurement group_id="O2" value="-0.4" spread="21.4"/>
                    <measurement group_id="O3" value="-0.3" spread="20.6"/>
                    <measurement group_id="O4" value="-7.4" spread="21.9"/>
                    <measurement group_id="O5" value="-9.0" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="25.3"/>
                    <measurement group_id="O2" value="-4.6" spread="21.3"/>
                    <measurement group_id="O3" value="-6.4" spread="21.5"/>
                    <measurement group_id="O4" value="-10.2" spread="24.7"/>
                    <measurement group_id="O5" value="-11.7" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="26.4"/>
                    <measurement group_id="O2" value="-7.5" spread="22.3"/>
                    <measurement group_id="O3" value="-8.8" spread="23.6"/>
                    <measurement group_id="O4" value="-11.4" spread="22.9"/>
                    <measurement group_id="O5" value="-16.3" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC VA 3.1A - Total Pain Score by Body Mass Index [BMI &lt;= 25]</title>
        <description>Analysis in normal-weight population (BMI &lt;= 25) of the WOMAC VA 3.1A score (range 0-500 mm) is reported.
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.</description>
        <time_frame>over the 3 weeks after the first administration</time_frame>
        <population>Population of Normal Weight patients (BMI &lt;=25)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC VA 3.1A - Total Pain Score by Body Mass Index [BMI &lt;= 25]</title>
          <description>Analysis in normal-weight population (BMI &lt;= 25) of the WOMAC VA 3.1A score (range 0-500 mm) is reported.
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.</description>
          <population>Population of Normal Weight patients (BMI &lt;=25)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="53.91"/>
                    <measurement group_id="O2" value="-72.4" spread="55.78"/>
                    <measurement group_id="O3" value="-109.0" spread="91.97"/>
                    <measurement group_id="O4" value="-109.0" spread="86.66"/>
                    <measurement group_id="O5" value="2.7" spread="75.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="97.88"/>
                    <measurement group_id="O2" value="-90.7" spread="70.94"/>
                    <measurement group_id="O3" value="-99.2" spread="39.89"/>
                    <measurement group_id="O4" value="-63.8" spread="90.05"/>
                    <measurement group_id="O5" value="-31.2" spread="71.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" spread="100.02"/>
                    <measurement group_id="O2" value="-110.7" spread="80.72"/>
                    <measurement group_id="O3" value="-107.8" spread="46.16"/>
                    <measurement group_id="O4" value="-112.9" spread="93.52"/>
                    <measurement group_id="O5" value="-62.3" spread="83.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WOMAC VA 3.1A - Total Pain Score by Body Mass Index -[BMI &gt; 25]</title>
        <description>Analysis in over-weight population (BMI &gt; 25) of the WOMAC VA 3.1A score (range 0-500 mm) is reported.
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.</description>
        <time_frame>over the 3 weeks after the first administration</time_frame>
        <population>Population of Over Weight patients (BMI &gt;25)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>WOMAC VA 3.1A - Total Pain Score by Body Mass Index -[BMI &gt; 25]</title>
          <description>Analysis in over-weight population (BMI &gt; 25) of the WOMAC VA 3.1A score (range 0-500 mm) is reported.
A decrease of the WOMAC VA 3.1 A score following treatment administration indicates a reduction of pain symptom.</description>
          <population>Population of Over Weight patients (BMI &gt;25)</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.5" spread="81.73"/>
                    <measurement group_id="O2" value="-62.9" spread="81.14"/>
                    <measurement group_id="O3" value="-56.4" spread="88.08"/>
                    <measurement group_id="O4" value="-67.4" spread="86.99"/>
                    <measurement group_id="O5" value="-58.0" spread="70.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.2" spread="83.18"/>
                    <measurement group_id="O2" value="-78.2" spread="75.67"/>
                    <measurement group_id="O3" value="-81.5" spread="105.08"/>
                    <measurement group_id="O4" value="-81.6" spread="90.11"/>
                    <measurement group_id="O5" value="-83.9" spread="72.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-103.4" spread="95.60"/>
                    <measurement group_id="O2" value="-122.1" spread="69.96"/>
                    <measurement group_id="O3" value="-114.1" spread="106.00"/>
                    <measurement group_id="O4" value="-99.6" spread="83.74"/>
                    <measurement group_id="O5" value="-103.3" spread="85.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Reports</title>
        <description>Incidence of spontaneously reported adverse events</description>
        <time_frame>up to 4 months after screening</time_frame>
        <population>The number of patients reflects all patients administered at least one dose of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Reports</title>
          <description>Incidence of spontaneously reported adverse events</description>
          <population>The number of patients reflects all patients administered at least one dose of the investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood / Lymph system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General / administration site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections / infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury / poisoning / procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic, and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical and medical procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social circumstances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Abnormal Laboratory Tests</title>
        <description>Percentage of patients with Abnormal Laboratory Tests judged Clinically Significant by Investigators.
The following hematochemical and urinary parameters were analysed:
Red Blood Cells Count, Haematocrit, Haemoglobin, Platelets, MCV, MCH, MCHC, White Blood Cells, Sodium, Chloride, Potassium, Total calcium, AST (SGOT), ALT (SGPT), GGT, Alkaline phosphatase, Total Bilirubin, Direct Bilirubin, Creatinine, BUN, CPK, LDH, Glucose, Total proteins, Albumin.</description>
        <time_frame>up to 4 months from screening</time_frame>
        <population>Percentage of patients with clinically significant abnormal laboratory tests</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O2">
            <title>Mid Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O3">
            <title>High Dose</title>
            <description>two doses</description>
          </group>
          <group group_id="O4">
            <title>Single High Dose</title>
            <description>one dose+placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>two doses</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Abnormal Laboratory Tests</title>
          <description>Percentage of patients with Abnormal Laboratory Tests judged Clinically Significant by Investigators.
The following hematochemical and urinary parameters were analysed:
Red Blood Cells Count, Haematocrit, Haemoglobin, Platelets, MCV, MCH, MCHC, White Blood Cells, Sodium, Chloride, Potassium, Total calcium, AST (SGOT), ALT (SGPT), GGT, Alkaline phosphatase, Total Bilirubin, Direct Bilirubin, Creatinine, BUN, CPK, LDH, Glucose, Total proteins, Albumin.</description>
          <population>Percentage of patients with clinically significant abnormal laboratory tests</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Alkaline Phophatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Fibrin D dimer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Four months of safety observation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose</title>
          <description>two doses</description>
        </group>
        <group group_id="E2">
          <title>Mid Dose</title>
          <description>two doses</description>
        </group>
        <group group_id="E3">
          <title>High Dose</title>
          <description>two doses</description>
        </group>
        <group group_id="E4">
          <title>Single High Dose</title>
          <description>one dose+placebo</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>two doses</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Supraventricular-tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Guillain Barré syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Uretric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Ureterocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director</name_or_title>
      <organization>Menarini-Ricerche</organization>
      <phone>+39-055-56809990</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

